Chapter 635: That **** monopoly!

The intelligence services of the United States are always paying attention to He Jiang's physical condition.

But when He Jiang was sent to Changzezhou, the intelligence department lost the source of intelligence.

Because Chang Zezhou is an isolated delta area, it is not in a big city, and there are no public facilities around it. In addition, Changtian Technology has done a very good job in security protection, so it is difficult for the intelligence department to penetrate.

Therefore, about He Jiang's physical condition, it is now a mystery.

However, according to the information obtained earlier by the intelligence department, especially the information obtained from 606 tertiary hospitals.

He Jiang is in the middle and late stages of small cell lung cancer.

According to the judgment of the intelligence department, 100% of small cell lung cancer has already begun to spread cancer cells.

A lifespan of three to five months is quite good.

In addition, the He family cannot get the most advanced targeted drug for small cell lung cancer - osimertinib, which is currently in clinical trials.

Therefore, the intelligence department judged that He Jiang is likely to die in Changzezhou within a few months.

Therefore, the intelligence department immediately dispatched intelligence personnel. On the one hand, they continued to lurk in Suzhou and Hangzhou in the Xia Kingdom, and kept an eye on He Jiang’s physical condition; on the other hand, they arranged for people to go to the medical departments of AstraZeneca and the United States to prohibit Oxi The effects of tinib and other small cell lung cancer targeted drugs are exported.

In addition to osimertinib, there are many targeted drugs for small cell lung cancer in the United States, but the effect is not as good as osimertinib, and the effect is not very good in the treatment of middle and advanced small cell lung cancer.

But in order to make He Jiang die as soon as possible, the intelligence department hopes that any pharmaceutical and drug manufacturer in the United States will prohibit the export of any targeted drugs to Xia.

It doesn't matter to the US intelligence agencies whether other cancer patients in Xia are dead or not, they want He Jiang to die as soon as possible.

Therefore, in order to let He Jiang die as soon as possible, the intelligence department can immediately cut off the supply of cancer-targeted drugs to Xia Guo.

Moreover, the United States and Xia Guo have no cooperation in this area in medicine. At present, all cancer-targeted drugs exported from the United States to Xia Guo are not commercial behaviors, but private behaviors.

Many methods are not yet formal.

It is also very simple to cut off the supply path, and there are no legal and commercial risks.

AstraZeneca is one of the largest pharmaceutical companies in the United States. First of all, he wants to meet the needs of consumers in the United States, and of course he will listen to the relevant departments and capital of the United States.

Therefore, when the intelligence department issued a warning, AstraZeneca immediately stopped exporting various anti-cancer targeted drugs to Xia Guo.

Osimertinib, which is undergoing clinical trials in the laboratory, has also stopped recruiting volunteers for clinical trials from Chinese in Xia Guo or the United States.

In the United States, there is a very cumbersome procedure for an emerging drug from research and development to final marketing.

One of the most critical aspects is clinical trials.

Americans feel that their names are very precious, so the subjects of clinical trials are basically not Americans.

Even in the United States, clinical trial participants are those patients who are terminally ill and have no way to treat them and want to try new drugs.

Most of the experimenters are from Asia and Africa, such as Xia, India and Southeast Asia.

These people may not be able to find suitable jobs after coming to the United States, and they are in urgent need of money, or they may not have obtained green cards from the United States, which are illegal immigrants.

They get a certain amount of money or a chance to survive in the United States by acting as a test subject for this very dangerous experiment.

After being warned by the intelligence services, all Chinese clinical trial subjects were excluded from AstraZeneca.

Xiaguo Shanghai Fudan University Affiliated Hospital Cancer Hospital.

The hospital has been in contact with AstraZeneca, hoping to introduce osimertinib from AstraZeneca.

The hospital and AstraZeneca have always had a good cooperative relationship. When AstraZeneca's many new drugs are used in Asia, the Cancer Hospital is also one of the first hospitals to use.

This time, the cancer hospital hopes to introduce osimertinib, and its purpose is to try every means to treat He Jiang.

Everyone knows that there is no cure for advanced small cell lung cancer.

However, if He Jiang's life can be extended through the latest targeted drugs, He Jiang can have a higher quality of life and more energy to complete the final research and development of the turbofan 10 engine, or choose a few disciples with all his heart and soul. Cultivate it and become your own successor, so that the purpose of the country will be achieved.

The person who contacted AstraZeneca was Ma Yongkai, the vice president of the Cancer Hospital.

Ma Yongkai studied in the United States in his early years, and was subsequently responsible for the hospital's equipment and medicines.

I have to admit that Xia Guo's medical technology and equipment are particularly backward in this era. Even the most advanced Fudan University Affiliated Hospital has a large technical gap with overseas medical centers or hospitals.

Ma Yongkai is responsible for connecting with overseas advanced medical equipment companies or pharmaceutical companies, and trying every means to introduce advanced drugs and equipment into the hospital.

The proton therapy equipment was introduced by Ma Yongkai from the United States, and it has indeed treated many cancer patients in the past few years.

Because of Ma Yongkai's strong contacts, he immediately contacted AstraZeneca after he received the order to immediately get osimertinib for the treatment of He Jiang.

And also obtained the default and permission of the other party.

The other party hopes that Ma Yongkai can send someone over to complete the procedures to get the medicine, and the name of the medicine is to cooperate with the clinical experiment in the United States.

After all, anti-cancer targeted drugs that have not been approved by the FDA are still quite precious and classified.

Without a valid reason and strong personal connections, it is simply impossible for ordinary people to get such drugs.

Ma Yongkai also convened a meeting of his subordinates and sent the most trusted team to the United States to get medicines.

But at this time, Ma Yongkai received a call from AstraZeneca's docking staff.

The other party informed Ma Yongkai that all the cooperation agreements discussed before were invalidated, Osimertinib is now prohibited from being sold in the name of experimental drugs, and it is impossible to bring Osimertinib to Xia by any means.

After receiving such information, Ma Yongkai was stunned.

It was clear that the two sides had a good discussion, and the air tickets were bought here, and they were going to go to the United States to get medicines immediately.

Cancel it now.

What is the reason?

When Ma Yongkai was about to ask the other party for the specific situation, he didn't know that the other party kept silent, that is to say, the cancellation was due to some force majeure.

When things go wrong, there must be demons.

Ma Yongkai is not a fool.

The clinical trial of osimertinib has lasted for more than half a year.

Before, Ma Yongkai also obtained related drugs from the United States through various means.

Even some wealthy people in Xia Guo obtained osimertinib in clinical trials through Ma Yongkang's relationship.

This shows that even though osimertinib is still in clinical trials, it has begun to be applied on a large scale through informal channels.

Since the rich used to spend a little money and have some connections to get the medicine, why can't they get it this time?

Ma Yongkai thought that the other party wanted a higher price, and through his personal relationship, he found the relevant person in charge of drug sales at AstraZeneca, saying that he could give a higher price, as long as he could get it Osimertinib.

However, Ma Yongkai got the news that AstraZeneca has received a clear request from the relevant U.S. departments, and a variety of lung cancer-targeted drugs, including osimertinib, are not allowed to be sold in Xia.

Among them, osimertinib circulating in other places shall not be resold to Xiaguo.

If AstraZeneca finds that related drugs have come to Xiaguo through other channels.

Then AstraZeneca will protect its rights and interests through legal means and fully terminate the cooperation with the other party.

This trick is quite intimidating.

In particular, AstraZeneca produces related drugs and some therapeutic devices, which have a wide range of markets around the world.

If the cooperation with the other party is terminated, then the partner will suffer heavy losses.

Moreover, the patents of AstraZeneca's devices and drugs are protected globally. If they resort to the law, companies and even individuals who cooperate with AstraZeneca will face considerable legal risks.

Under such high pressure, no one will take the risk and resell Osimertinib to Xia Guo.

After Ma Yongkai got the news, he was very anxious.

He believes that the current situation is not something he can handle.

And just a few months ago, medicines that even the rich could buy at high prices are now not available through hospitals, or even by the power of the state. This shows that the other party has made fundamental changes in the measures for medicines.

Ma Yongkai knew that he would definitely not be able to buy medicines at his own level, so he had to report the situation to the relevant departments of Yanjing immediately.

The relevant departments of Yanjing and Xia Guo obtained the root cause of this incident through some intelligence channels.

That is, the United States learned that He Jiang, the chief designer of Taihang Engine, had small cell lung cancer and needed osimertinib urgently, so it terminated the supply to Xia Guo.

Not only He Jiang, but many Xiaguo patients who were waiting for the drug to be treated were out of stock for a while, sometimes waiting to die.

After learning the news, Liang Fei, a person in charge of a relevant department in Xia Guo, patted the table angrily and said, "These American people are waiting for our chief designer to die on the bed!"

Anger and venting were followed by a burst of emptiness and helplessness.

There is no way, because there is a big gap between medical technology and the United States. The United States, similar to AstraZeneca, Pfizer and other companies, has a very strong monopoly power in the medical industry.

It is the freedom of others not to sell you medicine, and there is nothing you can do on your side.

What's more, nominally, similar to targeted drugs for the treatment of tumors, the United States and Xia have no relevant business exchanges and trade cooperation, and most of them are black market transactions.

So you are really helpless.

Seeing that Liang Fei was angry, his subordinates were silent and did not dare to make a sound.

In order to treat He Jiang, Xia Guo was a multi-departmental linkage, and immediately sent He Jiang to Tianyue Island of Changtian Technology, and asked the Fudan University Affiliated Cancer Hospital to fully assist the treatment with top-level equipment and medical staff.

Thanks to the strong medical technology of Changtian Technology Respiratory Center, He Jiang's condition has been stabilized, but this temporary stability does not mean a complete solution to the problem.

Liang Fei immediately arranged for his subordinates, "You guys go to Mumbai to have a look. AstraZeneca has a corresponding pharmaceutical factory in Mumbai."

The largest natural clinical trial plant for US pharmaceutical companies such as AstraZeneca is in India.

Asan's government also encourages this. After all, India is a caste system, and the lives of lower castes are worthless.

And these poor people are the natural testing ground for American pharmaceutical companies.

One is to use these poor people as experiments. The price is very cheap. It may be tens of meters or hundreds of meters to complete the experiments that would take tens of millions of meters to complete in the United States.

Because these people don't have to be responsible for paying some money after they die.

The second is to carry out the pharmaceutical industry in India. There are not so many cumbersome procedures, and there is even no need to consider the probability of error. After all, if it is wrong, the dead will not be responsible.

Therefore, global pharmaceutical companies, especially those in the United States, especially like to move their clinical laboratories to India.

But it's not free either.

India allows you to come and do experiments on the premise that I can imitate your technology without restrictions and produce related drugs without taking into account your patents.

In response to this condition put forward by India, the US pharmaceutical companies also turned a blind eye, not admitting it, but not completely denying it.

Therefore, India is an internationally recognized cheap drug library. Many cancer-targeted drugs with a course of up to tens of thousands of meters can be purchased here, and the price is much cheaper than the genuine one.

Liang Fei was sure that the United States would cut off all purchase channels for Osimertinib in Xia, so he would settle for the next best thing and let the staff go to India to purchase related drugs.

After all, they could wait, but He Jiang couldn't.

Cancer cells grow very fast.

They are in a race against time.

Liang Fei directly contacted the representative of the state-owned pharmaceutical company in India and asked the relevant staff to go directly to the pharmaceutical factory in Mumbai.

Soon Mumbai got the latest news.

All the generic drugs of osimertinib have been discontinued, not only people from Xiaguo can not buy it, but also people from other countries can not buy it.

It would be strange to say that there is no pressure from the US side of the world.

Liang Fei was furious when he heard the news.

Now the relevant departments have thought of all the ways, but because of the monopoly of the United States on high-end anti-cancer drugs, He Jiang has no cure.

Liang Fei hates it very much Why can't Xia Guozhi's medical industry break the US monopoly on cancer-targeted drugs?

Liang Fei also felt that he was powerless and unable to complete the tasks assigned by the organization.

He and his team can only buy other class 1 and 2 targeted drugs at high prices from the black market in the United States and use them instead of osimertinib.

But Liang Fei himself also knows that this kind of targeted drug is almost useless for advanced small cell lung cancer.

Liang Fei was only notified of the relevant news to the superior department and Changtian Technology, hoping that Changtian Technology could take some measures by scientific means.

At this moment, Chen Xiao and Qu Ping are in the VIP ward of the intensive care center.

He Jiang was barely able to sit on the bed, but he was wearing a ventilator and would gasp for breath after saying a few words. The situation was very bad.

Qu Ping received a call, hurried out, and hurried back, and finally whispered a few words to Chen Xiao.